Low vitamin D and elevated immunoreactivity against Epstein-Barr virus before first clinical manifestation of multiple sclerosis.
J Neurol Neurosurg Psychiatry. 2012 Aug 11.
Décard BF, von Ahsen N, Grunwald T, Streit F, Stroet A, Niggemeier P, Schottstedt V, Riggert J, Gold R, Chan A.
Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.
Vitamin D deficiency and Epstein-Barr virus (EBV) infection may be associated with the development of multiple sclerosis (MS). We investigated serum 25-hydroxyvitamin D (25-OH-D) levels and anti-EBV immunoreactivity in 25 individuals before the first clinical manifestation of MS.
PATIENTS AND METHODS:
56 serum samples of 25 individuals who had donated blood prior to the first clinical MS manifestation (clinically isolated syndrome (CIS)) (four male subjects, 21 female subjects, mean age 31.5 years at time of pre-CIS blood sampling; mean age at disease onset 33.4 years) were available, covering an interval of 7.3 years-2 months (mean 31.5 months) before CIS.
In 18 of 25 patients serum samples were also obtained after established diagnosis of MS. Longitudinal age- and gender-matched healthy blood donors (four male subjects, 21 female subjects, 39 samples, mean age 32.5 years) served as controls. Serum 25-OH-D was measured by isotope dilution-liquid chromatography-tandem mass spectrometry. 25-OH-D levels were deconvoluted using published seasonal coefficients from a German population. Immunoglobulin G (IgG) against Epstein-Barr virus nuclear antigen-1 (EBNA1) were assessed using commercially available ELISA.
Low 25-OH-D levels were observed during the 24-month pre-CIS interval (47.8 (32.5-77.2) nmol/l, median (IQR); healthy controls: 81.6 (57.7-98.5), p=0.004, however, still higher than after established diagnosis (24.5 (13.7-47.7), p<0.0001 compared with controls).
IgG against EBNA1 during the 36-month pre-CIS interval was increased (185.9 (91.2-460.0) IU/ml, median (IQR); healthy controls 63.7 (29.5-121.6), p=0.002).
Low vitamin D and remote EBV infection may be associated with clinical MS breakthrough within 2-3 years.
– – – – – – – –
- 19 ng 2 years before diagnosis
- 10 ng at time of MS diagnosis
- Overview MS and vitamin D
Clinical trials for MS and Vitamin D 18 as of Sept 2012
Vitamin D being used for MS more than any other disease
3 books with sections on MS and vitamin D
Vitamin D found to be far better than FDA drug for MS
Many MS websites are very pro vitamin D
People at risk of having low vitamin D (elderly, women, blacks,...) have greater incidence of MS
- Vitamin D reduces multiple sclerosis relapses, but not with interferon treatment – June 2012
Perhaps because the interferon had already increased the vitamin D levels
- Hypothesis:Vitamin D Epstein-Barr interaction increases MS risk – Sept 2011
- All items in category MS and vitamin D
- Google search of VitaminDWiki for Epstein-Barr 60 items Sept 2012
- MS causes explored - vitamin D is in 2 of the 4 - 2009 which has the following chart
Low vitamin D levels became even lower when diagnosed with MS – Sept 2012
- MS is in a vicious cycle with vitamin D: low D ==> MS which lowers vitamin D
CLICK HERE for more about deficiencies and vicious cycles
1800 visitors, last modified 28 Sep, 2012,